Literature DB >> 33588946

Ethical care requires pragmatic care research to guide medical practice under uncertainty.

Tim E Darsaut1, Jean Raymond2.   

Abstract

BACKGROUND: The current research-care separation was introduced to protect patients from explanatory studies designed to gain knowledge for future patients. Care trials are all-inclusive pragmatic trials integrated into medical practice, with no extra tests, risks, or cost, and have been designed to guide practice under uncertainty in the best medical interest of the patient. PROPOSED REVISION: Patients need a distinction between validated care, previously verified to provide better outcomes, and promising but unvalidated care, which may include unnecessary or even harmful interventions. While validated care can be practiced normally, unvalidated care should only be offered within declared pragmatic care research, designed to protect patients from harm. The validated/unvalidated care distinction is normative, necessary to the ethics of medical practice. Care trials, which mark the distinction and allow the tentative use of promising interventions necessarily involve patients, and thus the design and conduct of pragmatic care research must respect the overarching rule of care ethics "to always act in the best medical interest of the patient." Yet, unvalidated interventions offered in contexts of medical uncertainty cannot be prescribed or practiced as if they were validated care. The medical interests of current patients are best protected when unvalidated practices are restricted to a care trial protocol, with 1:1 random allocation (or "hemi-prescription") versus previously validated care, to optimize potential benefits and minimize risks for each patient.
CONCLUSION: Pragmatic trials can regulate medical practice by providing (i) a transparent demarcation between unvalidated and validated care; (ii) norms of medical conduct when using tests and interventions of yet unknown benefits in practice; and eventually (iii) a verdict regarding optimal care.

Entities:  

Keywords:  Clinical trials; Equipoise; Evidence based medicine; Medical care; Research ethics; Therapeutic obligation

Mesh:

Year:  2021        PMID: 33588946      PMCID: PMC7885344          DOI: 10.1186/s13063-021-05084-0

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  45 in total

1.  [Science and ethics, therapeutic misconception and mirage].

Authors:  J Raymond; H Long
Journal:  J Neuroradiol       Date:  2008-06-05       Impact factor: 3.447

2.  Unruptured intracranial aneurysms: why clinicians should not resort to epidemiologic studies to justify interventions.

Authors:  J Raymond; T E Darsaut; M Kotowski; M W Bojanowski
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-08       Impact factor: 3.825

Review 3.  The Introduction of Innovations in Neurovascular Care: Patient Selection and Randomized Allocation.

Authors:  Robert Fahed; Tim E Darsaut; Jean Raymond
Journal:  World Neurosurg       Date:  2018-06-23       Impact factor: 2.104

4.  An Ethical Analysis of the SUPPORT Trial: Addressing Challenges Posed by a Pragmatic Comparative Effectiveness Randomized Controlled Trial.

Authors:  Austin R Horn; Charles Weijer; Jeremy Grimshaw; Jamie Brehaut; Dean Fergusson; Cory E Goldstein; Monica Taljaard
Journal:  Kennedy Inst Ethics J       Date:  2018

Review 5.  The 2018 ter Brugge Lecture: Problems with the Introduction of Innovations in Neurovascular Care.

Authors:  Jean Raymond; Robert Fahed; Daniel Roy; Tim E Darsaut
Journal:  Can J Neurol Sci       Date:  2019-02-21       Impact factor: 2.104

6.  Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated health care systems, 1996-2010.

Authors:  Rebecca Smith-Bindman; Diana L Miglioretti; Eric Johnson; Choonsik Lee; Heather Spencer Feigelson; Michael Flynn; Robert T Greenlee; Randell L Kruger; Mark C Hornbrook; Douglas Roblin; Leif I Solberg; Nicholas Vanneman; Sheila Weinmann; Andrew E Williams
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

7.  The second wave: Toward responsible inclusion of pregnant women in research.

Authors:  Anne Drapkin Lyerly; Margaret Olivia Little; Ruth Faden
Journal:  Int J Fem Approaches Bioeth       Date:  2008

8.  Target ranges of oxygen saturation in extremely preterm infants.

Authors:  Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

9.  When is informed consent required in cluster randomized trials in health research?

Authors:  Andrew D McRae; Charles Weijer; Ariella Binik; Jeremy M Grimshaw; Robert Boruch; Jamie C Brehaut; Allan Donner; Martin P Eccles; Raphael Saginur; Angela White; Monica Taljaard
Journal:  Trials       Date:  2011-09-09       Impact factor: 2.279

10.  A randomized pragmatic care trial on endovascular acute stroke interventions (EASI): criticisms, responses, and ethics of integrating research and clinical care.

Authors:  Robert Fahed; Stefanos Finitsis; Naim Khoury; Yan Deschaintre; Nicole Daneault; Laura Gioia; Gregory Jacquin; Céline Odier; Alexande Y Poppe; Alain Weill; Daniel Roy; Tim E Darsaut; Thanh N Nguyen; Jean Raymond
Journal:  Trials       Date:  2018-09-19       Impact factor: 2.279

View more
  2 in total

1.  Flow Diversion in the Treatment of Intracranial Aneurysms: A Pragmatic Randomized Care Trial.

Authors:  J Raymond; D Iancu; W Boisseau; J D B Diestro; R Klink; M Chagnon; J Zehr; B Drake; H Lesiuk; A Weill; D Roy; M W Bojanowski; C Chaalala; J L Rempel; C O'Kelly; M M Chow; S Bracard; T E Darsaut
Journal:  AJNR Am J Neuroradiol       Date:  2022-08-04       Impact factor: 4.966

Review 2.  Pragmatic trials can address diagnostic controversies: recent lessons from gestational diabetes.

Authors:  Jean Raymond; Hélène Long; Tim Darsaut
Journal:  Trials       Date:  2022-04-01       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.